RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Zai Lab of Shanghai was approved in Hong Kong to market Zejula® (niraparib), an oral, once-daily PARP inhibitor for adult ovarian cancer patients. The approval of Zejula was based on the global Phase III trial of Zejula sponsored by Tesaro. Zai in-licensed China rights (including Hong Kong) to the drug from Tesaro in 2016. It is Zai’s first marketing approval, and the company expects to launch Zejula before the end of the year. Zai is continuing to conduct China trials of Zejula.
Source: China Biotoday